Expression Of Ki-67 And C-erbB-2 Before And After Neoadjuvant Chemotherapy And Relation With Pathological Response In Breast Cancer

Objective:To observe the expressions of Ki-67 and C-erbB-2 before and after neoadjuvant chemotherapy in bresst cancer patients,and to investigate its discuss the relation with chemotherapy effect.Methods:45 cases of breast cancer were diagnosed by core biopsies,to the expressions of Ki67 and C-erbB-2 in cancer tissue were measured by immunohistochemistry before and after NAC with Epirubicin and Paclitaxel (EPI+PTX)regimen for 2 cycles, and the histopathologic response of surgical specimens after NAC were observed.Results:After NAC,3 patients(6.67%)achieved pathological complete response(pCR),29 patients(64.44%)pathological part response(pPR), and 13 cases(28.89%)pathological stable disease(pSD).The total response rate was 71.11%.The Ki-67 positive expression rate after NAC was much lower, there was a significant difference between the Ki-67 positive expression rate after NAC and that before NAC (p＜0.05),while there was no significant difference in the expression of C-erbB-2 between before and after chemotherapy (p>0.05);and pathologic effective rate was much higher than that in Ki-67 negative expression patients (p<0.05),But between C-erbB-2 overexpressed group and C-erbB-2 non-overexpressed group,there were not statistical significance (p>0.05)Conclusion:NAC with ET(EPI+PTX)regimen is effective,it can inhibit the proliferation of cancer cell,and in patients with the Ki-67 positive expression, the NAC has better effect,it could be a prognostic for its response to NAC in breast cancer.